ArticleNature reviews. Materials2023
New Opportunities and Old Challenges in the Clinical translation of Nanotheranostics.
Article in Nature reviews. Materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed.
- Advancing PROTAC therapeutics through chemistry-guided design of smart delivery systems.Acta pharmacologica Sinica · 2026Review
- Smart Theranostic Nanoplatforms in Oral Squamous Cell Carcinoma: Integrating Diagnosis, Targeted Therapy and Synergistic Photothermal/Photodynamic Approaches.International journal of molecular sciences · 2026Review
- Tumour-specific bioorthogonal synthesis of proteolysis-targeting chimeras and nanoparticles boosts T cell activity.Nature biomedical engineering · 2026Article
- From bench to bulk: exploring in-line homogenization for scale-up and continuous production of vesicular systems.Drug delivery and translational research · 2026Article
- pH-Dependent Surface Charge Modulation of Peptide-Coated Poly(lactic-co-glycolic Acid) (PLGA) Nanoparticle for Drug Delivery in Ovarian Cancer.Molecules (Basel, Switzerland) · 2026Article
- Accelerating the clinical translation of bioengineered anticancer therapeutics.Journal of the National Cancer Center · 2026Article
- Curcumin-loaded tetrahedral framework nucleic acids reshape intestinal homeostasis in ulcerative colitis by coordinating barrier repair, microbiota reconstruction, and immune modulation.Materials today. Bio · 2026Article
- ROS-responsive nanoplatform-mediated targeted intranasal delivery of Piezo2 siRNA for the treatment of trigeminal neuralgia.Materials today. Bio · 2026Article
- Nanozymes for ferroptosis-based cancer theranostics.Bioactive materials · 2026Review
- Breast Cancer: Epidemiology, Molecular Classification, Diagnostics and Evolving Treatment Paradigms.Molecules (Basel, Switzerland) · 2026Review
- Transforming stroke care: the promise of feedback-guided thrombolytic nanomedicine.Journal of nanobiotechnology · 2026Review
- Multifunctional Nano-Contrast Agent Carriers: From Traditional Platforms to Next-Generation Theranostic Applications in Molecular Imaging.Biomedicines · 2026Review
- Next-Generation Strategies to Encounter Antimicrobial Resistance (AMR): From Lariocidin to Gene Editing and Nanotechnology-Based Approaches.Molecules (Basel, Switzerland) · 2026Review
- Nanoparticle-Based Biomaterials in Cancer Research: From Mechanistic Insights to Therapeutic Innovation.International journal of molecular sciences · 2026Review
- Engineered Neutrophils in Translational Medicine: Gene Editing, Nanotechnology, and AI-Driven Clinical Breakthroughs.Advanced healthcare materials · 2026Review
- Nano-enabled spatially selective protein degradation modulates lactate metabolism to potentiate antitumor immunity in liver cancer.Nature nanotechnology · 2026Article
- Bridging solubility, stability, and translation: advances in carbon nanotube-based drug delivery systems.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Tumor-Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Barrier-Oriented Design of Next-Generation Polymeric Nanocarriers for Targeted Drug Delivery.Molecules (Basel, Switzerland) · 2026Review
- Nanotechnology in triple-negative breast cancer: a review of nanocarrier systems for enhanced efficacy and reduced toxicity.Nanoscale advances · 2026Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nanoparticle-based systems imbued with both diagnostic and therapeutic functions, known as nanotheranostics, have enabled remarkable progress in guiding focal therapy, inducing active responses to endogenous and exogenous biophysical stimuli, and stratifying patients for optimal treatment. However, although in recent years more nanotechnological platforms and techniques have been implemented in the clinic, several important challenges remain that are specific to nanotheranostics. In this Review, we first discuss some of the many ways of 'constructing' nanotheranostics, focusing on the different imaging modalities and therapeutic strategies. We then outline nanotheranostics that are currently used in humans at different stages of clinical development, identifying specific advantages and opportunities. Finally, we define critical steps along the winding road of preclinical and clinical development and suggest actions to overcome technical, manufacturing, regulatory and economical challenges for the safe and effective clinical translation of nanotheranostics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.